立訊精密(002475.SZ):3.05億元增資常熟立芯
格隆匯1月21日丨立訊精密(002475.SZ)公佈,為提升核心競爭力,結合公司經營發展情況,公司計劃增資全資子公司常熟立芯科技有限公司(“常熟立芯”)。
立訊精密以自有資金3.05億元增資其全資子公司常熟立芯。此次增資完成後,常熟立芯註冊資本將由1.8億元增至4.85億元。
公司通過增資常熟立芯購地建廠,持續提升消費電子智能模組產品產能儲備和深化系統封裝製造服務,全方位提升市場地位與核心競爭力。同時,可充分發揮公司自身垂直整合優勢,進一步豐富公司產品結構,促進公司可持續發展,滿足公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.